CAJ | 학술논문

目的评估腹腔热灌注化疗(HIPC)对于预防与治疗腹膜假性黏液瘤(PMP)减瘤术后复发的疗效和安全性.方法在PubMed等数据库中检索2010年以前发表的相关文献,根据评估方案综合研究结果.结果通过文献的纳入、排除标准和质量评估,最终有11篇文献入选.入选文献中的患者中位随访时间22～60个月;中位生存期25.6～156.0个月;1、2、3、5和10年的生存率分别为72%～100%、55%～96%、59%～96%、52%～96%和55%～96%.减瘤术后HIPC化疗药物不良反应发生率为2%～15%,围手术期死亡率为0～7%.结论 PMP患者减瘤术后予以HIPC治疗安全、有效.
목적 평고복강열관주화료(HIPC)대우예방여치료복막가성점액류(PMP)감류술후복발적료효화안전성.방법 재PubMed등수거고중검색2010년이전발표적상관문헌,근거평고방안종합연구결과.결과통과문헌적납입、배제표준화질량평고,최종유11편문헌입선.입선문헌중적환자중위수방시간22～60개월;중위생존기25.6～156.0개월;1、2、3、5화10년적생존솔분별위72%～100%、55%～96%、59%～96%、52%～96%화55%～96%.감류술후HIPC화료약물불량반응발생솔위2%～15%,위수술기사망솔위0～7%.결론 PMP환자감류술후여이HIPC치료안전、유효.
Objective To evaluated the safety and efficacy of hyperthermic intraperitoneal perfusion chemotherapy (HIPC) in the prevention and treatment of pseudomyxoma peritonei (PMP)recurrence after cytoreductive surgery (CRS). Methods Studies published in English before 2010 on HIPC after CRS for PMP were searched in PubMed database. Each study was carefully evaluated based on pre-determined criteria. Study results were comprehensively displayed in a form. A descriptive systematic review was performed. Results A total of 11 studies were included. The median survival time of patients in these studies ranged from 25.6 months to 156 months. The ranges of 1-year, 2-year,3-year, 5-year, and 10-year survival rates were 72%-100%, 55%-96%, 59%-96%, 52%-96%, and 55%-96%, respectively. The overall complication rate ranged from 2%-15%, and the total perioperative mortality were from 0 to 7%. Conclusion HIPC after CRS is effective and safe for patients with PMP.